Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Millennium Management Llc Sells 7,666 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $32.12, for a total value of $246,231.92. Following the completion of the transaction, the insider owned 144,974 shares in the company, valued at $4,656,564.88. The trade was a 5.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $28.12, for a total value of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.81, for a total value of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.61, for a total value of $23,629.68.
• On Monday, March 30th, Millennium Management Llc purchased 9,533 shares of Sensei Biotherapeutics stock. The shares were purchased at an average price of $25.86 per share, for a total transaction of $246,523.38.
• On Friday, March 27th, Millennium Management Llc purchased 15,321 shares of Sensei Biotherapeutics stock. The shares were purchased at an average price of $26.61 per share, for a total transaction of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc purchased 5,731 shares of Sensei Biotherapeutics stock. The shares were purchased at an average price of $28.62 per share, for a total transaction of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total value of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total value of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc purchased 6,175 shares of Sensei Biotherapeutics stock. The shares were purchased at an average price of $34.49 per share, for a total transaction of $212,975.75.
• On Tuesday, March 31st, Millennium Management Llc purchased 6,005 shares of Sensei Biotherapeutics stock. The shares were purchased at an average price of $28.16 per share, for a total transaction of $169,100.80.

Sensei Biotherapeutics Stock Up 3.1%

Shares of SNSE opened at $20.43 on Friday. Sensei Biotherapeutics, Inc. has a 12-month low of $5.25 and a 12-month high of $36.76. The firm has a market capitalization of $27.38 million, a price-to-earnings ratio of -1.23 and a beta of -0.18. The stock’s 50-day moving average price is $28.89 and its 200 day moving average price is $17.87.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($130.83). Equities research analysts expect that Sensei Biotherapeutics, Inc. will post -2.77 EPS for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the period. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 10.50% of the company’s stock.

Wall Street Analysts Forecast Growth

SNSE has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. Wall Street Zen lowered Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Leerink Partners initiated coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective on the stock. Finally, Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $40.00.

More Sensei Biotherapeutics News

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.